Treatment of chronic hyperuricaemia in adults where urate deposition has already occurred (including history or presence of tophus &/or gouty arthritis). Feburic 120 mg is also indicated for prevention & treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).
Not recommended in patients w/ ischaemic heart disease or CHF; Lesch-Nyhan syndrome; organ transplant patients. Closely monitor patients for symptoms of allergic/hypersensitivity reactions. Gout flares may occur during treatment initiation. Perform liver function test prior to treatment initiation & periodically thereafter based on clinical judgment. Use w/ caution in patients w/ altered thyroid function. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Concomitant use w/ mercaptopurine/azathioprine. Severe renal impairment. Moderate to severe hepatic impairment. May impair ability to drive or operate machinery. Should not be used during pregnancy & lactation. Childn <18 yr.
Increased plasma conc of mercaptopurine/azathioprine. Possible increased metabolism & decreased efficacy w/ potent UGT enzyme inducers. Naproxen, NSAIDs, probenecid & other inhibitors of glucuronidation could in theory affect the elimination of febuxostat.
Manage Account
Change Password
Sign Out
